|
DNA and Cell Biology
Overall Survival in Women with Breast Cancer: The Influence of Pepsinogen C Gene Polymorphism
To cite this article:
Ana L. Pinto-Correia, Daniela Pinto, Deolinda Pereira, Helena Rodrigues, Joaquim Abreu de Sousa, Hugo Sousa, Berta Sousa, Susana Sousa, Carlos Lopes, Rui Medeiros.
DNA and Cell Biology.
June 2008,
27(6): 333-336.
doi:10.1089/dna.2007.0713.
Published in Volume: 27 Issue 6: June 12, 2008
Online Ahead of Print: April 30, 2008
Ana L. Pinto-Correia Molecular Oncology Group, Portuguese Institute of Oncology, Porto, Portugal. Daniela Pinto Molecular Oncology Group, Portuguese Institute of Oncology, Porto, Portugal. Virology Department, Portuguese Institute of Oncology, Porto, Portugal. Deolinda Pereira Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. Helena Rodrigues Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. Joaquim Abreu de Sousa Surgical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. Hugo Sousa Molecular Oncology Group, Portuguese Institute of Oncology, Porto, Portugal. ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal. Berta Sousa Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. Susana Sousa Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. Carlos Lopes Molecular Oncology Group, Portuguese Institute of Oncology, Porto, Portugal. ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal. Rui Medeiros Molecular Oncology Group, Portuguese Institute of Oncology, Porto, Portugal. Surgical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal. ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal. We aimed to study the role of an insertion/deletion polymorphism in the Pepsinogen C (PGC) gene in the clinical outcome of 172 breast cancer patients. The six polymorphic alleles were amplified using PCR. Our results indicate that patients carrying the allele 6 present a higher 5-year survival mean (83.4% of 6 allele carriers were alive at 5 years vs. only 68.6% of noncarriers, p=0.001), suggesting a role for this polymorphism in the outcome of breast cancer patients. We hypothesize that PGC polymorphism can be a predictive biomarker in breast cancer, contributing to an individual profile of great interest in clinical oncology. |
|
TOC Alert
CiteULike
Delicious
Digg This
Facebook
Newsvine